Royal Bank Of Canada Reaffirms “Sector Perform” Rating for Aardvark Therapeutics (NASDAQ:AARD)

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “sector perform” rating reissued by equities research analysts at Royal Bank Of Canada in a research note issued to investors on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock. Royal Bank Of Canada’s price target would indicate a potential upside of 8.89% from the stock’s previous close.

A number of other brokerages also recently weighed in on AARD. Wall Street Zen raised shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $15.33.

Aardvark Therapeutics Price Performance

NASDAQ AARD traded down $0.05 on Thursday, hitting $5.51. 73,302 shares of the stock were exchanged, compared to its average volume of 235,530. The business’s fifty day moving average is $6.20 and its 200 day moving average is $5.28. Aardvark Therapeutics has a 52 week low of $3.35 and a 52 week high of $17.94. The company has a market capitalization of $120.58 million, a PE ratio of -1.72 and a beta of 3.74.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.21. Analysts predict that Aardvark Therapeutics will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling at Aardvark Therapeutics

In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the sale, the insider owned 35,475 shares in the company, valued at approximately $183,760.50. This represents a 63.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 17.80% of the company’s stock.

Institutional Investors Weigh In On Aardvark Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AARD. BlackRock Inc. bought a new stake in Aardvark Therapeutics in the 2nd quarter valued at $1,077,000. Susquehanna International Group LLP bought a new position in shares of Aardvark Therapeutics during the 2nd quarter valued at approximately $138,000. Ieq Capital LLC purchased a new position in shares of Aardvark Therapeutics during the 2nd quarter worth about $221,000. J. Goldman & Co LP bought a new position in shares of Aardvark Therapeutics during the second quarter valued at approximately $233,000. Finally, Renaissance Technologies LLC bought a new position in Aardvark Therapeutics in the 1st quarter valued at $267,000.

Trending Headlines about Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and maintained a $6.00 price target, implying roughly 10% potential upside from the recently cited $5.46 price. The rating indicates a neutral outlook rather than a strong bullish endorsement. Benzinga analyst rating report
• Neutral Sentiment: Brokerage coverage was reported at a consensus “hold” recommendation, suggesting analysts remain cautious and see limited near-term catalysts. Aardvark brokerage consensus report
• Negative Sentiment: Several law firms, including SBS, Bernstein Liebhard, Hagens Berman, Rosen, Levi & Korsinsky, and Faruqi & Faruqi, announced or promoted a securities class action involving investors who purchased Aardvark shares in or after the February 2025 IPO and through May 14, 2026. The repeated announcements increase visibility around the company’s legal exposure and may pressure investor sentiment. Bernstein Liebhard shareholder alert
• Negative Sentiment: The complaint alleges that Aardvark’s disclosures portrayed ARD-101 as largely confined to the gut and without serious adverse events or key organ-safety limitations, while allegedly failing to provide sufficient detail about cardiac safety risks. The allegations relate to a subsequent Phase 3 trial pause and full FDA clinical hold; they have not been proven in court. Investors have until October 13, 2026, to seek lead-plaintiff status. SueWallSt Aardvark lawsuit notice

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for obesity, hyperphagia and related metabolic disorders. The company’s approach is based on activating bitter taste receptors, which it believes may influence appetite regulation and metabolic signaling without relying on injectable therapies.

Aardvark’s lead investigational product, ARD-101, is an oral small-molecule bitter taste receptor agonist being studied for conditions involving excessive hunger and food intake, including hyperphagia associated with Prader-Willi syndrome.